We are committed to quality and focus our capabilities to ensure that our services meet or exceed our customer's expectations. In compliance with highest professional standards, we continuously advance our quality management system, that defines the scope for improving our performance.
… scientific expertise for your objectives
acromion GmbH is a European, independent, privately owned, full-service Contract Research Organization (CRO) with years of experience in medical and bioscientific research. We support our customers in developing pharmaceuticals, biologics and medical devices, both for the human and the veterinary market. We provide full-service in trial organization and conduct, clinical monitoring, clinical data management, statistics, quality assurance and medical writing for phase I to IV clinical and non-interventional (NIS) trials in the context of your projects.
… competency, transparency, accountability
Your team will benefit from the secure knowledge that we take responsibility for the accurate performance of all tasks that we are assigned to. Due to our long-standing capability in managing complex projects with many involved parties we identify upcoming issues and pro-actively present and initiate measures for improvement.
acromion is very experienced in conducting clinical trials as the leading member within a network of service providers. We are open in adopting the sponsor’s SOPs and in collaborating with already established partners. The work in such partnership is highly appreciated ensuring that common effort
and reciprocal support is made for a most excellent study outcome.
Measuring and reporting progress in course of a trial is imperative. You can rely on being provided regularly on schedule and promptly on demand with information, and being alerted of all issues that require your attention.
Once assigned to a project our team is taking the responsibility for its successful outcome and the obligation to accuratelly report and explain all actions during its lifetime. You will find the peace of mind knowing that the A-team is in charge of your project.
Data Protection Certified
Talking about „being different“: acromion GmbH proudly presents its team of highly qualified
specialists. For us “Human resources” are the heart of the matter. Therefore, we cherish the
long-term professional experience of our team as our most valued resource. Gain from the
profound knowledge of our employees in clinical research - physicians, statisticians,
pharmacologists, biologists and all-rounders - who will be glad to stand by your side.
Excellence: Meet our team and rely on their expertise in a large variety of therapeutic areas
International scientific research needs multifold skills in international communication. Naturally, our staff is fluent in German and English. Furthermore, native speakers of Italian, Spanish, Danish, Swedish, Polish, Greek, Corean, Hungarian and Romanian rank among our team, and you may also rely on proficient skills in other European languages, e.g., French or Dutch.
From highway A1
Take the exit ‘Frechen’ at the highway crossing Cologne-West (A1/A4) and turn right on the B264 (Dürener Str.) direction ‘Frechen’.
Leave the B264 at the next traffic light and turn right on the Kölner Str. (L277). Turn right again at the 1st possibility (there are two right-turn lines, please use the left one), follow the road, pass around ‘Porta’ and turn left at the roundabout into ‘Europaallee’.
Follow ‘Europaallee’ to the next roundabout and then turn right. The office building is located 100 m further on the left hand side.
From airport Cologne/Bonn
The airport is 17.4 miles (28 km) away.
Take any city rail to Cologne central station ‘Köln Hbf’. Take from here S-Bahn (city rail) line 12 direction ‘Düren’ to stop ’Köln Weiden-West’. For detailed scheduled information please refer to: DB Bahn
From there you can take the bus no 965 (direction ‘Frechen Grube Carl’). The bus leaves every 30 minutes and takes about 10 minutes. Alternatively you may take a taxi (5 minutes).
From the city of Cologne
Tram line 7 (from city center direction ‘Frechen Benzelrath’) to the stop ‘Frechen Rathaus’; change at ‘Frechen Rathaus’ onto bus line 976 (direction ‘Frechen Briefzentrum’) or bus line 965 (direction Cologne ‘Weiden-West’) to the stop ‘Frechen Briefzentrum’
S-Bahn (city rail from the central station ‘Hbf’) lines 12 direction ‘Düren’ to ’Köln Weiden-West’
Tram line 1 (from city center to ‘Köln Weiden-West’) to terminal stop
Change at ‘Köln Weiden-West’ onto bus line 965 (direction ‘Frechen Grube Carl’) to stop ‘Frechen Briefzentrum’.
The annual SYMPOSIUM will take place on November 25, 2022, in the Westin Grand Hotel in Munich
The annual SYMPOSIUM will take place on November 26, 2021, in the Service Congress Center (SCC) in Munich
A day to celebrate our achievements and successes and a day to appreciate our colleagues and employees for their dedication and efforts, and our partners for their support, and our customers for their trust and encouragement.
BIO Deutschland und der Arbeitskreis der BioRegionen veranstalten seit 2010 die jährlichen, zweitägigen Deutschen Biotechnologietage (DBT) als Forum für den Erfahrungsaustausch zwischen allen Akteuren der deutschen Biotechnologieszene.
36. Jahreskongress Pharmazeutische Medizin in Berlin
5th European Conference of Clinical Research in Amsterdam
Acromion is attending the EUCROF conference.
The European funded projects CARAMBA and EURE-CART are organising a joint CAR-T Regulatory Workshop on Jan 30th 2020, right before the 2nd CAR-T cell meeting (Sitges).
This open workshop will be a great opportunity to share experiences gained during CARAMBA and EURE-CART and discuss key regulatory aspects of the CAR-T cell product, against the background of different national regulations on GMOs.
The annual SYMPOSIUM will take place on November 29, 2019, in the Sheraton Arabellapark Hotel in Munich
The European Union has awarded EURE-CART (EURopean Endeavour for Chimeric Antigen Repector Therapies) with 5 Million Euro within the Horizon 2020 – Research and Innovation Framework Programme, section reserved to the new therapies for chronic diseases (including cancer).